Detalhe da pesquisa
1.
Risk of fatigue and anemia in patients with advanced cancer treated with olaparib: A meta-analysis of randomized controlled trials.
Crit Rev Oncol Hematol
; 141: 163-173, 2019 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-31306986